GOLDEN & COLORADO SPRINGS, Colo., Jun 15, 2010 — Vitro Diagnostics, Inc., and HemoGenix(R), Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world. The new products extend the well established HALO(R) assay platform for hematopoietic stem cells to now include mesenchymal stem cells and induced pluripotent stem cells (iPS) as well. These new high performance assays provide an ability to analyze stem cells for determination of quality, potency and response to toxic agents. Through a previously established alliance, these new products are jointly manufactured by Vitro and HemoGenix(R), Inc. Vitro provides its specialized stem cell media and stem cells while HemoGenix(R) provides the LUMENESC(TM) and LumiSTEM(TM) ATP bioluminescent readout reagents and materials.
Dr. Ivan Rich, CEO and founder of HemoGenix(R), Inc., that was recently featured as a leading provider of cell-based products for drug discovery and development (Drug Discovery & Development, May 1, 2010) said, “We are very pleased to introduce the LUMENESC(TM)-Hu assay for mesenchymal stem cells and LumiSTEM(TM) for induced pluripotent stem cells. We have developed a regulatory-compliant method for stem cell analysis and look forward to establishing our method as the gold standard for new therapies based on advances in stem cell technology.”
About HemoGenix(R), Inc.
HemoGenix(R), (http://www.hemogenix.com/) a privately held life sciences company located in Colorado Springs, Colorado, was founded in 2000 by Ivan N. Rich, Ph.D., an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. HemoGenix(R) was formed as a Contract Research Service Laboratory for stem cell hemotoxicity testing. Dr. Rich subsequently developed, patented and commercialized the HALO(R) Assay Platform, a state-of-the-art quantitative assay for hematopoietic stem cells. The HALO(R) Assay replaces the older colony-forming assay of stem cells which has many disadvantages including variable results resulting in a lack of quantization.
HemoGenix(R), Inc. now offers over 1,000 different catalog items including, HALO(R), LUMENESC(TM), LumiSTEM(TM) and OxyFLOW(TM) Kits all over the world to biotechnology and pharmaceutical companies and academic institutions.
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells(TM)” for the advancement of regenerative medicine to its full potential. Vitro also owns pending U.S. patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development(TM)”, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.